๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

25 recruiting trials

for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration NCT06662162NA13 sites๐Ÿ“ Poway๐Ÿ“ Manchester๐Ÿ“ Lemont i-Lumen Scientific AUS PTY LTD ยท Tests: i-Lumen AMD SGLT2 Inhibitors in Geographic Atrophy NCT07174687Phase 21 site๐Ÿ“ St Louis Washington University School of Medicine ยท Tests: Dapagliflozin, Matching Placebo A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) NCT06635148Phase 2, Phase 3104 sites๐Ÿ“ Tucson๐Ÿ“ Fullerton๐Ÿ“ La Jolla Janssen Research & Development, LLC ยท Tests: JNJ-81201887, Sham Procedure Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD NCT07770828Phase 33 sites๐Ÿ“ Phoenix๐Ÿ“ Erie๐Ÿ“ McAllen Ocugen ยท Tests: OCU410 A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration NCT03178149Phase 120 sites๐Ÿ“ Phoenix๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto Astellas Institute for Regenerative Medicine ยท Tests: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy NCT06541704Phase 3231 sites๐Ÿ“ Chandler๐Ÿ“ Phoenix๐Ÿ“ Phoenix Regeneron Pharmaceuticals ยท Tests: Pozelimab, Cemdisiran, Placebo Safety & Efficacy of Eyecyte-RPEโ„ข in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. NCT06394232Phase 1, Phase 23 sites๐Ÿ“ Jฤlna๐Ÿ“ Delhi๐Ÿ“ Hyderabad Eyestem Research Pvt. Ltd. ยท Tests: Eyecyte-RPEโ„ข A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration NCT07851259Phase 25 sites๐Ÿ“ Walnut Creek๐Ÿ“ Winston-Salem๐Ÿ“ Erie Genentech, Inc. ยท Tests: RO7965032, Placebo A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) NCT07144137n/a19 sites๐Ÿ“ Mountain View๐Ÿ“ Oak Forest๐Ÿ“ Springfield Complement Therapeutics Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration NCT04847635NA3 sites๐Ÿ“ Genova๐Ÿ“ Milan๐Ÿ“ Rome Ospedale San Raffaele ยท Tests: Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan), Pascal Synthesis 577 sham (Topcon Corporatโ€ฆ A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration NCT06765980Phase 1, Phase 24 sites๐Ÿ“ Erie๐Ÿ“ Ottawa๐Ÿ“ Tel Aviv Kriya Therapeutics, Inc. ยท Tests: VV-14295 Phase 2 Study of ADX-038 in Participants With Geographic Atrophy NCT06990269Phase 283 sites๐Ÿ“ Gilbert๐Ÿ“ Phoenix๐Ÿ“ Bakersfield ADARx Pharmaceuticals, Inc. ยท Tests: ADX-038, Placebo A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio NCT07215390Phase 278 sites๐Ÿ“ Gilbert๐Ÿ“ Mesa๐Ÿ“ Phoenix Apellis Pharmaceuticals, Inc. ยท Tests: APL-3007, pegcetacoplan (APL-2), APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy NCT07668804Phase 1, Phase 23 sites๐Ÿ“ Hurstville๐Ÿ“ Sydney๐Ÿ“ Launceston Theratocular Biotek Co. ยท Tests: TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injection Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy NCT07531927NA5 sites๐Ÿ“ Hamburg๐Ÿ“ Mรผnchen๐Ÿ“ Stuttgart Okuvision GmbH ยท Tests: Transcorneal electrical stimulation (TES) with the OkuStim 2 System, Transcorneal electrical stimulation (TES) with theโ€ฆ A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration NCT07441642Phase 259 sites๐Ÿ“ Huntington Beach๐Ÿ“ Sacramento๐Ÿ“ Santa Barbara Novartis Pharmaceuticals ยท Tests: FWY003, Placebo Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration NCT07160179Phase 1, Phase 25 sites๐Ÿ“ Carmel๐Ÿ“ Reno๐Ÿ“ Abilene AbbVie ยท Tests: ABBV-6628, SYFOVRE An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA) NCT07392255Phase 1, Phase 28 sites๐Ÿ“ Carmel๐Ÿ“ Reno๐Ÿ“ Dallas Complement Therapeutics ยท Tests: CTx001 A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD NCT06659549Phase 224 sites๐Ÿ“ Beverly Hills๐Ÿ“ Walnut Creek๐Ÿ“ Hagerstown Galimedix Therapeutics Inc ยท Tests: GAL-101, Placebo A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251 NCT05626114Phase 217 sites๐Ÿ“ Beverly Hills๐Ÿ“ Sacramento๐Ÿ“ San Francisco Genentech, Inc. ยท Tests: OpRegen A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration NCT07215234Phase 1, Phase 235 sites๐Ÿ“ Peoria๐Ÿ“ Scottsdale๐Ÿ“ Beverly Hills Sanofi ยท Tests: SAR446597, Sham Comparator A Study in Adults With Geographic Atrophy NCT07606365Phase 256 sites๐Ÿ“ Bakersfield๐Ÿ“ Beverly Hills๐Ÿ“ Aurora Sitala Bio LTD ยท Tests: STL303, Placebo Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants NCT07230834Phase 19 sites๐Ÿ“ Lakewood๐Ÿ“ East Weymouth๐Ÿ“ Austin Regeneron Pharmaceuticals ยท Tests: Pozelimab A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration NCT07029945Phase 1, Phase 217 sites๐Ÿ“ Gilbert๐Ÿ“ Phoenix๐Ÿ“ Hattiesburg Biojiva LLC ยท Tests: BRX011, Placebo A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD NCT07158775Phase 1, Phase 21 site๐Ÿ“ Edison Bionic Sight LLC ยท Tests: BS01, Sham procedure control
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy